Is Innovation-Led Growth Driving ISRG's Revenues Above Procedures?

Intuitive Surgical’s ISRG first-quarter 2026 results highlight a widening divergence between revenue growth (23%) and procedure growth (17%), signaling the increasing role of innovation-led monetization in its business model. This gap reflects not only volume expansion but also pricing power and a favorable product mix, particularly driven by the ramp-up of the da Vinci 5 platform.

A key driver is the premium pricing and higher system utilization of the da Vinci 5, which is accounting for a growing share of placements and usage. Management noted that revenue growth outpacing procedure growth is largely attributable to the differentiated value of the da Vinci 5 platform, which supports accretive pricing, greater integration and incremental trade-in activity. Supporting this trend, average selling prices rose to nearly $1.7 million, alongside an increase in instruments and accessories (I&A) revenue per procedure, partly driven by a higher mix of da Vinci 5 and SP procedures.

This dynamic reflects what management termed ‘innovation-led revenue growth’ — a model in which differentiated technology enables Intuitive Surgical to capture incremental value beyond procedure volumes. The company is effectively monetizing advanced features such as Force Feedback instrumentation, digital integration and AI-enabled capabilities, which enhance clinical outcomes and workflow efficiency, thereby justifying premium pricing.

The sustainability of this revenue-procedure spread will depend on market mix. Management acknowledged a “push and pull” dynamic — where premium innovation supports pricing in developed markets, but cost-sensitive geographies and procedures may require price concessions or lower-cost offerings, such as refurbished Xi systems.

The first-quarter result underscores a structural shift in ISRG’s growth model — from purely volume-driven expansion to a more value-based monetization strategy. While the current spread appears sustainable in the near term, its durability will hinge on continued innovation differentiation and the company’s ability to balance pricing power with global affordability dynamics.

Peer Updates

Abbott ABT delivered modest top-line growth in the first quarter of 2026, with comparable sales rising 3.7% and EPS up 6%, better than market expectations. Revenue drivers were diversified, including new product launches (PFA catheters), strength in emerging markets pharmaceuticals (up 9%) and contributions from the Exact Sciences acquisition.

Procedure-linked businesses — particularly Medical Devices — remained strong, led by cardiovascular segments such as electrophysiology (up 13%) and heart failure (up 12%), indicating healthy underlying procedural volumes.

Diagnostics growth was constrained by a weaker respiratory testing season, highlighting sensitivity to episodic testing demand. Overall, Abbott’s growth was supported by procedure recovery, innovation and portfolio breadth, despite near-term diagnostic headwinds.

Boston Scientific BSX delivered a solid first-quarter 2026 performance, with organic sales growth of 9.4% and revenues reaching $5.2 billion (+11.6% YoY), reflecting strong underlying procedural demand. Procedure volumes remained robust across key franchises, particularly in electrophysiology (+22%), cardiovascular (+11%) and neuromodulation (+15%), highlighting sustained adoption of minimally invasive therapies.

This growth was driven by innovation-led platforms such as FARAPULSE, WATCHMAN and interventional oncology technologies, alongside strong international momentum. However, some procedure softness emerged in WATCHMAN late in the quarter due to capacity and workflow constraints.

Overall, BSX’s revenues were supported by high procedure intensity, new product launches and global market expansion.

ISRG’s Price Performance, Valuation and Estimates

Shares of ISRG have lost 19.1% so far this year compared with an 11.4% decline for the industry.

Image Source: Zacks Investment Research

From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 46.59, above the industry average. But, it is still lower than its five-year median of 70.50. ISRG carries a Value Score of D.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies an 11.5% rise from the year-ago period’s level.

Image Source: Zacks Investment Research

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Source Zacks-com